Horobin JM, Preece PE, Dewar JA, et al. Long term follow-up of elderly patients with locoregional breast cancer treated with tamoxifen only[J]. Br J Surg, 1991, 78(2): 213-217.
[5]
Diab SG, Elledge RM, Clark GM. Tumor characterstics and clinical outcome of elderly women with breast canaer[J]. J Natl Cancer Inst, 2000, 92(7): 550-556.
[6]
Semiglazov VF, Semiglazov VV, Dashyan GA, et al. Phase 2 radomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor positive breast cancer[J]. Cancer, 2007, 110(2): 244-254.
[7]
Gazet JC, Markopoulos C, Food HT, et al. Prospective randomized trial of tamxifen vs surgery in elderly patients with breast cancer[J]. Eur J Surg Oncol, 1994, 20(3): 207-214.
[8]
Eiermann W, Paepke S, Appfelstaedt L, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study[J]. Ann Oncol, 2001, 122(11): 1527-1532.
[9]
Cataliotti L, Buzdar A, Noguchi S, et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative “Arimidex” Compared to Tamoxifen (PROACT) trial[J]. Cancer, 2006, 106(10): 2095-2103.〖ZK)〗
[10]
Smith IE, Dowsett M, Ebbs SR, et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial[J]. J Clin Oncol, 2005, 23(22): 5108-5116.
[11]
Semiglazov VF, Semiglazov VV, Ivanov VG, et al. Exemestane(E) vs tamoxifen(T) as neoadjuvant endocrine therapy for postmenopausal women with ER+ breast cancer (T2NH, T3N0-1 T4 NOMO)[J]. J Clin Oncol, 2005, 23(165): 530.
[12]
Dixon JM, Jackson J, Renshaw L, et al. Neoadjuvant tamoxifen and aromatase inhibitors: comparisons and clinical outcomes[J]. J Steroid Biochem Mol Biol, 2003, 86(3-5): 295-299.
[13]
Fennessy M, Bates T, MacRae K, et al. Late follow-up of a randomized trial of surgery plus tamoxifen versus tamoxifen alone in women aged over 70 years with operable breast cancer[J]. Br J Surg, 2004, 91(6): 699-704.
[14]
Mustacchi G, Ceccherini R, Milani S, et al. Tamoxifen alone versusadjuvant tamoxifen for operable breast cancer of the elderly: long-term results of the phase Ⅲ randomized controlled multicenter GRETA trial[J]. Ann Oncol, 2003, 14(13): 414-420.
[15]
Kaufmann M, Hortobagyi GN, Goldhirsch A, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update[J]. J Clin Oncol, 2006, 24(12): 1940-1949.
[16]
Paepke S, Tulusan A, Kiesel L, et al. A multi-center study of pre-operative treatment with letrozole for optimal duration of treatment in postmenopausal women with ER and/or PGR positive breast cancer[J]. Proc Am Soc Clin Oncol, 2003, 22: 321.
